NeueHealth (NEUE) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, and welcome to New Health's First Quarter twenty twenty five Earnings Conference Call. As a reminder, this call is being recorded. Leading the call today are New Health's President and CEO, Mike Mikan and CFO, Jay Matuszak. Before we begin, we want to remind you that this call may contain forward looking statements under U. S. Federal securities laws. These statements are subject to risks and uncertainties that could cau ...

Financial Data and Key Metrics Changes - Acacia recorded total revenue of $124.4 million during the first quarter, a significant increase compared to the same quarter last year [21] - The company reported first quarter GAAP operating income of $38.3 million, compared to a GAAP operating loss of $2.1 million in the same quarter last year [23] - GAAP net income attributable to Acacia was $24.3 million or $0.25 per share, compared to a net loss of $0.2 million or $0 per share in the prior year period [24] - Adjusted net income attributable to Acacia was $33.1 million or $0.34 per share [24] - Cash, cash equivalents, and equity securities at fair value totaled $290 million as of March 31, 2025, compared to $297 million at December 31, 2024 [25] Business Line Data and Key Metrics Changes - Energy operations generated $18.3 million in revenue for the quarter, compared to $1.9 million in the same quarter of last year [21] - Manufacturing operations generated $28.5 million in revenue [21] - Industrial operations generated $7.7 million in revenue during the quarter, a slight decrease from $8.8 million in the same quarter last year [21] - Intellectual property operations generated $69.9 million in licensing and other revenue during the quarter, compared to $13.6 million in the same quarter last year [22] Market Data and Key Metrics Changes - Benchmark's energy segment has hedged over 70% of its production through the end of 2027, providing price protection and cash flow predictability [11] - Approximately 51% of Benchmark's last twelve months (LTM) revenue and 78% of LTM production was driven by gas and natural gas liquids, which have remained resilient [11] Company Strategy and Development Direction - The company focuses on acquiring and building businesses with stable long-term cash flow generation and scalability [6] - Acacia is actively evaluating strategic acquisitions and organic growth initiatives across its verticals [27] - The company is exploring avenues to monetize its Cherokee position and is monitoring attractive M&A targets due to recent oil price softness [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Acacia's resilience amid macroeconomic uncertainties and believes the current environment presents compelling opportunities [27] - The company is focused on disciplined cost management and operational excellence to navigate volatile periods [16] - Management highlighted the strong performance driven by realized gains from the intellectual property business and the integration of Revolution assets [7][14] Other Important Information - Total consolidated G&A expense was $17.3 million during the first quarter, an increase from $12.5 million in the same quarter last year, primarily due to the addition of Deflecto [22] - The company has zero capital commitments from a drilling perspective, allowing it to remain cash flow positive even in challenging price environments [11] Q&A Session Summary Question: Can you detail the total winnings from the WiFi portfolio? - Management indicated that since Q1 2023, approximately $178 million has been generated from the WiFi assets, with ongoing cases potentially adding more value [31] Question: Are you seeing prices coming down in M&A? - Management noted they are looking at three verticals: energy, industrials, and mature technology, with ongoing evaluations of acquisition opportunities [33][34] Question: What is the calculus on protecting tax attributes versus share buybacks? - Management confirmed they completed a $20 million buyback while monitoring tax attributes to determine the optimal time for further buybacks [40] Question: Does the recent settlement put pressure on the defendant in the $37 million judgment case? - Management expressed uncertainty but hoped that the recent settlement would encourage a quicker resolution [49]

Groupon (GRPN) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Hello, and welcome to Groupon's First Quarter twenty twenty five Financial Results Conference Call. On the call today are Chief Executive Officer, Dushan Sanketfel Chief Financial Officer and Senior Vice President of Finance, Rana Keshat. At this time, all participants are in a listen only mode. Today's call will be a question and answer session only. The company has posted earnings materials, including its earnings commentary on the com ...

AxoGen (AXGN) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director Nir Naor, Chief Financial Officer and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter twenty twenty five financial results and corporate highlights. Nir will then provide an analysis of our financial performance and guidance and discuss our outlook for the year, followed by a question and answer session. ...

Financial Data and Key Metrics Changes - In Q1 2025, the company generated revenue of $1.3 billion, reflecting an 11.7% year-over-year increase on a reported basis [27] - Organic constant currency revenue grew by 1.4% compared to Q1 2024, exceeding initial expectations of flat organic growth [27] - GAAP gross margin for the quarter was 26.9%, down from 28.4% in Q1 2024, while non-GAAP gross margin was 28.7%, compared to 30.4% in the same period last year [32][33] - GAAP income from operations was $99 million (7.6% of revenue), down from $111 million (9.5% of revenue) in Q1 2024 [34] - Non-GAAP diluted EPS was $2.41, a decrease from $2.46 in Q1 2024 [34] Business Line Data and Key Metrics Changes - Financial services delivered strong growth of 29.3% year-over-year, with 4.5% organic growth in constant currency, driven by strength in insurance, banking, and payments [28] - Software and high-tech grew by 9.6% year-over-year, while life sciences and healthcare increased by 10.5% [28] - Consumer goods, retail, and travel decreased by 1.4% year-over-year, largely due to declines in consumer products and retail [29] - Emerging verticals delivered very strong growth of 22.8%, positively impacted by Neoris Industrial Materials customers [29] Market Data and Key Metrics Changes - The Americas, representing 60% of Q1 revenues, grew by 12.6% year-over-year, while EMEA, representing 38% of revenues, increased by 10.7% [30] - APAC, representing 2% of revenues, saw a growth of 4.3% year-over-year [30] - Revenues from the top 20 clients grew by 6.1% year-over-year, while revenues from clients outside the top 20 increased by 14.6% [31] Company Strategy and Development Direction - The company is focused on driving organic growth and maintaining momentum in AI-related capabilities, which are expected to continue throughout the year [10][19] - A planned leadership transition is underway, with Balas Feyros set to become the new CEO on September 1, 2025, indicating a strategic shift towards AI-native transformation [7][8] - The company aims to improve gross margins and utilization rates while navigating macroeconomic uncertainties [33][66] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the second half of 2025, despite macroeconomic uncertainties, citing strong client demand and engagement [12][15] - The company has not seen a material slowdown in client spending, with ongoing improvements in demand for services [39] - Management highlighted a trend of clients returning to EPAM for quality execution after experiencing underperformance with other partners [15] Other Important Information - The company reported cash flow from operations of $24 million in Q1, down from $130 million in the same quarter of 2024, attributed to higher bonus payments and increased days sales outstanding (DSO) [35] - Free cash flow was $15 million, compared to $123 million in Q1 2024 [35] - The company ended Q1 with over 61,700 employees, reflecting total growth of 18.2% and organic growth of 6.4% compared to Q1 2024 [36] Q&A Session Summary Question: Can you provide more color on the second half confidence and underlying macro? - Management indicated that the outlook for the second half remains consistent with previous projections, with no significant changes observed in client purchasing behavior [51][53] Question: How should we expect free cash flow to trend as we move through the year? - Management expects free cash flow conversion to remain around 80% to 90%, with elevated DSO likely to persist due to fixed fee revenues [58][59] Question: Are you sensing any pricing power as organic demand picks up? - Management stated it is too early to call for pricing increases, noting that improvements in demand are still relatively small [60] Question: Can you discuss plans to improve gross margin over the remainder of the year? - Management highlighted seasonal factors that typically benefit the second half and emphasized a renewed focus on improving utilization [65] Question: What are the growth dynamics within customer cohorts? - Management noted a visible trend of clients returning, contributing to improvements in revenue growth outside the top 20 clients [71][72]

T. Rowe Price Group (TROW) FY 2025 Annual General Meeting May 08, 2025 08:00 AM ET Speaker0 Hello and welcome to the Rowe Price twenty twenty five Annual Meeting of Stockholders. I will now turn the meeting over to Rob Sharp, Chairman of the Board, CEO and President to begin. Please go ahead. Speaker1 Good morning and welcome to the T. Rowe Price Group twenty twenty five Annual Meeting of Stockholders. I'm Rob Sharps, Chair of the Board, CEO and President and I will preside over today's meeting which is bei ...

Intellia Therapeutics (NTLA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Intellia First Quarter twenty twenty five Financial Results Conference Call. My name is Drew, and I will be your conference operator today. Following formal remarks, we will open the call up for a question and answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants ...

Financial Data and Key Metrics Changes - The company achieved a non-IFRS gross margin of 18.2%, an increase from 15.1% in the same quarter last year [19] - Operating expenses were reduced by $9,600,000, a decrease of 32.1% compared to Q1 2024 [7][19] - Adjusted net loss decreased by 36.5% to $10,900,000 from $17,200,000 in Q1 2024 [7] - Adjusted EBITDA increased to $14,300,000, up from $10,200,000 in the same quarter last year, representing a 40% increase [17][19] - Total revenue dropped by 4.5% year-over-year on a constant currency basis [17] Business Line Data and Key Metrics Changes - Energy business revenue was $34,500,000, showing a 6.2% growth year-over-year [8][17] - Hardware sales revenue was $29,100,000, down 21.8% year-over-year, attributed to a decrease in vehicle sales volume [18] - The total subscriber base reached 644,000, an 8% increase from 595,000 subscribers at the end of Q1 2024 [17] Market Data and Key Metrics Changes - The company anticipates that approximately 95% of its full-year revenue for 2025 will be generated from the Taiwan market [21] - The Taiwan two-wheeler market in 2025 is expected to remain at approximately 2024 levels [21] Company Strategy and Development Direction - The company aims to achieve breakeven in the energy business by 2026 and in the vehicle business by 2028 [6][21] - A new credit facility of approximately $61,500,000 has been secured to support growth and indicates market confidence [7] - The company is focusing on operational efficiency and cost optimization to drive profitability [20] Management's Comments on Operating Environment and Future Outlook - The global macro environment presents challenges, including market volatility and tariff issues, impacting consumer confidence [16] - Management remains focused on long-term growth and profitability, emphasizing the importance of the subscription-based business model [22] - The company is optimistic about the future, expecting to reach profitability in its battery swapping business by 2026 [21] Other Important Information - The company transferred its listing from the NASDAQ Global Select Market to the NASDAQ Capital Market, gaining an additional 180-day grace period for compliance [29] - The company continues to receive support from the Taiwan government for EV policies and infrastructure investments [14] Q&A Session Summary Question: How does the company view advancements in fast charging technology? - Management recognizes advancements in fast charging as beneficial for overall EV adoption but does not see them as a direct threat to its battery swapping model, which offers speed and convenience [24][25] Question: What are the plans regarding the transfer to the NASDAQ Capital Market? - The company has gained a grace period to regain compliance with NASDAQ requirements and is focused on long-term financial improvements rather than short-term stock price gains [29][30] Question: What are the long-term growth plans for top and bottom lines? - The company anticipates significant growth driven by its subscription model and expects operational leverage to improve profitability as revenue increases [32][33] Question: Is the current operating efficiency model sustainable as the company grows? - Management believes the operating efficiency model is sustainable and scalable, allowing for growth without a linear increase in operating costs [36][38]

Financial Data and Key Metrics Changes - The company reported total revenue of $1.4 billion, reflecting a 4% growth on a reported basis and 1% organic growth, with organic growth excluding $148 million from CSL and the whole blood divestiture at 8% [7][8] - Adjusted gross margin for the fourth quarter was 60.2%, an increase of 620 basis points compared to the prior year, driven by volume growth and improved product mix [24][25] - Adjusted net income for fiscal year 2025 was $231.5 million, up $28 million or 14%, with adjusted earnings per diluted share at $4.57, a 15% increase compared to the prior year [29] Business Line Data and Key Metrics Changes - Hospital revenue grew 12% in the quarter and 24% in fiscal year 2025 on a reported basis, with organic growth of 9% respectively [11] - Blood Management Technologies revenue grew 6% in the quarter and 10% in fiscal year 2025, driven by strong utilization and share gains [11] - The Interventional Technologies franchise delivered 21% reported growth in the quarter and 46% in fiscal year 2025, with 16% organic growth respectively [13] Market Data and Key Metrics Changes - Plasma revenue declined 9% in the quarter and 6% in fiscal year 2025, but excluding CSL, plasma revenue grew 11% in the fourth quarter and 5% for fiscal year 2025 [18][20] - Blood center revenue declined 22% in the quarter and 8% in fiscal year 2025 on a reported basis due to the whole blood divestiture [21] - The company anticipates plasma revenue to decline 7% to 10% on a reported basis in fiscal year 2026, with organic growth excluding CSL expected to be 11% to 14% [20] Company Strategy and Development Direction - The company is focused on advancing its innovation agenda and reallocating resources towards higher growth opportunities following the divestiture of the whole blood business [28] - A new regional and market alignment initiative is expected to generate approximately $30 million of net savings over the next two years [28] - The company aims for both blood management technologies and interventional technologies to become billion-dollar franchises each [66] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the strong growth trajectory of the hospital business, projecting reported and organic revenue growth of 8% to 11% in fiscal year 2026 [16] - The company expects adjusted operating margin to improve by 200 to 300 basis points, reaching 26% to 27% in fiscal year 2026 [33] - Management highlighted the importance of cash flow generation and expects free cash flow in fiscal year 2026 to be in the range of $160 million to $200 million [35] Other Important Information - The company executed a $150 million share buyback, repurchasing approximately 2.4 million shares, reflecting its commitment to value creation [10] - The adjusted income tax rate was 22% for the fourth quarter and 23% for fiscal year 2025, compared to 21% to 23% for the respective periods of the prior year [28] Q&A Session Summary Question: Insights on plasma collections and guidance for fiscal year 2026 - Management remains bullish on plasma, indicating that the 11% to 14% growth guidance is primarily driven by share gains and technology adoption, with modest growth expected in the first half of fiscal year 2026 [43][45] Question: Clarification on EPS guidance and operating margin drivers - The operating margin guidance of 26% to 27% is supported by continued gross margin improvement and operational leverage, with a $0.20 impact from tariffs factored into the guidance [47][49] Question: Update on vascular closure portfolio and legacy business performance - The company is focusing on driving utilization and share gains in the vascular closure market, with a dedicated team addressing both new and legacy products [55][60] Question: Changes in strategy following management transitions - The leadership changes are aimed at enhancing focus on growth in the hospital segment, with expectations for both blood management and interventional technologies to reach billion-dollar franchises [66][67] Question: Update on M&A activities and potential acquisition of VIVUSURE Medical - The company maintains a long-term appetite for strategic acquisitions, with optimism regarding the VIVUSURE opportunity, which aligns with its focus on closure and structural heart segments [74][76]

Financial Data and Key Metrics Changes - As of March, the company had cash and cash equivalents of $260 million, an increase from $165 million at the end of 2024, indicating a strong financial position following recent financing [12] - Cash used in operations for the first quarter was $45.7 million, with an expected net cash usage for the full year 2025 projected to be between $120 million to $145 million [13] Business Line Data and Key Metrics Changes - The company announced the completion of dosing for all participants in Part A of its pivotal Phase III trial for treatment-resistant depression (TRD), with top-line results expected in late June [5] - The Phase III program aims to confirm the durability and safety profile of COMM360, which could provide a groundbreaking treatment option for TRD patients if successful [9] Market Data and Key Metrics Changes - The company is focusing on the commercialization of COMM360 by developing relationships with various provider types through strategic collaborations, including a new partnership with HealthPort to enhance access to innovative mental health treatments [10] Company Strategy and Development Direction - The company is preparing for the commercialization of COMM360 by understanding the commercial opportunity and ensuring broad delivery across various care settings [9] - The strategic collaboration with HealthPort aims to address the needs of underserved populations, reflecting the company's commitment to equitable access to mental health treatments [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Phase III data readout, emphasizing the potential of COMM360 to be a clinically differentiated treatment option for TRD [13] - The company is also working on the final design for a late-stage clinical program in PTSD, indicating a significant commercial opportunity in this area due to high unmet needs [13] Other Important Information - The independent Data Safety Monitoring Board (DSMB) is regularly reviewing unblinded safety data, with a focus on suicidality, which remains a critical concern in the context of TRD [6][39] Q&A Session Summary Question: Key takeaways from the long-term follow-up data on durability and appropriate dosing - Management noted that while the data is not definitive, it suggests that patients receiving 25 mg can experience effects lasting up to six months, indicating this dose may be preferred moving forward [21] Question: Efficacy delta on MADRS and placebo effect considerations - Management acknowledged the variability in placebo effects in psychedelic trials and estimated a clinically significant effect size of over three on the MADRS scale [29] Question: Concerns regarding suicidality signals - Management clarified that suicidality is a core feature of depression and must be included in study designs, with ongoing monitoring to ensure safety [36] Question: Current delivery of esketamine by HealthPort - HealthPort has experience delivering SPRAVATO and is motivated to ensure access to new treatment options for underserved populations [42] Question: Manufacturing supply chain and FDA inspections - The company is currently manufacturing in the UK and plans to add US manufacturing capabilities, with multiple inspections conducted over the years [49] Question: Patient enrollment in COMM-five and comparison to Phase 2b - Management confirmed that recruitment criteria remain consistent, suggesting similar patient profiles across studies [55] Question: Interest in large pharma partnerships - The company is committed to commercializing COMM360 independently in the US, with no current plans for large pharma partnerships [58] Question: Optimal time frame for assessing suicidality risk post-treatment - Management indicated that predictions are difficult, and they will rely on data to inform their understanding of suicidality risk [61] Question: Changes in FDA interactions regarding psychedelic therapies - Management reported no significant changes in FDA interactions, maintaining routine discussions around event reporting [63]